Return of the lysergamides. Part III: Analytical characterization of N6-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P–ETH-LAD)
Simon D. Brandt, Pierce V. Kavanagh, Folker Westphal, S. Elliott, Jason Wallach, Alexander Stratford, D. Nichols, Adam L. Halberstadt
Drug Testing and Analysis May 10, 2017 DOI: 10.1002/dta.2196 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Laboratory characterization study Peer reviewed |
|---|---|
| Duration | 0-6 hours with hourly measurements and one measurement after 24 hours |
| Topics | LSD |
| Citations | 44 |
| Key points | 1P-ETH-LAD converts to ETH-LAD in human serum, suggesting it may act as a pro-drug. |
Abstract
The psychoactive properties of lysergic acid diethylamide (LSD) have fascinated scientists across disciplines and the exploration of other analogues and derivatives has been motivated by deepening the understanding of ligand-receptor interactions at the molecular level as well as by the search for new therapeutics. Several LSD congeners have appeared on the new psychoactive substances (NPS) market in the form of blotters or powders. Examples include 1-propionyl-LSD (1P–LSD), AL-LAD, and LSZ. The absence of analytical data for novel compounds is a frequent challenge encountered in clinical and toxicological investigations. Two newly emerging lysergamides, namely N6-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1P–ETH-LAD, were characterized by gas chromatography–mass spectrometry (GC–MS), low and high mass accuracy electrospray MS(/MS), GC solid-state infrared analysis, high performance liquid chromatography diode array detection as well as nuclear magnetic resonance spectroscopy. Limited analytical data for ETH-LAD were previously available, whereas information about 1P–ETH-LAD has not previously been encountered in the scientific literature. This study extends the characterization of lysergamides distributed on the NPS market, which will help to make analytical data available to clinicians, toxicologists, and other stakeholders who are likely to encounter these substances. The analysis of a test incubation of 1P–ETH-LAD with human serum at 37°C by LC single quadrupole MS at various time points (0–6 h, once per hour and one measurement after 24 h) revealed the formation of ETH-LAD, suggesting that 1P–ETH-LAD might serve as a pro-drug. 1P–ETH-LAD was still detectable in serum after 24 h.
Citations in the library
Cited by 29
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms Pharmacological Reviews December 16, 2020
- Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD) ACS Chemical Neuroscience February 20, 2018
- Return of the lysergamides. Part V: Analytical and behavioural characterization of 1‐butanoyl‐d‐lysergic acid diethylamide (1B‐LSD) Drug Testing and Analysis May 13, 2019
- Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM‐775) Drug Testing and Analysis June 5, 2017
and 24 more in the library
Cites 10
- Structural Features for Functional Selectivity at Serotonin Receptors Science March 21, 2013
- Structural Basis for Molecular Recognition at Serotonin Receptors Science March 22, 2013
- Crystal structure of an LSD-bound human serotonin receptor Cell January 26, 2017
- The new drug phenomenon Drug Testing and Analysis July 1, 2014
- Lysergamides of Isomeric 2,4-Dimethylazetidines Map the Binding Orientation of the Diethylamide Moiety in the Potent Hallucinogenic Agent N,N-Diethyllysergamide (LSD) Journal of Medicinal Chemistry September 1, 2002
and 5 more in the library